Hemophilia A Pipeline, FDA Approvals, Clinical Trials Developments, and Companies | Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., and others.
DelveInsight's, "Hemophilia A Pipeline Insights" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Hemophilia A pipeline landscape. It covers the Hemophilia A pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia A pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Key Takeaways from the Hemophilia A Pipeline Report
• DelveInsight's Hemophilia A pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Hemophilia A treatment.
• The leading companies working in the Hemophilia A Market include Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenix Pharmaceutical, Spark Therapeutics, Octapharma, ApcinteX Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics LLC, CSL Behring, and others.
• Promising Hemophilia A Pipeline Therapies in the various stages of development include Emicizumab, rFVIIa, aPCC, BAX 888, OBIZUR, BIIB031 (rFVIIIFc), Recombinant Human Coagulation FVIII, and others.
• July 2023: Apcintex Ltd announced a study of phase 2 clinical trials for SerpinPC. The purpose of the study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of prophylactic SerpinPC administered subcutaneously (SC) to participants with severe hemophilia A (HemA) (with or without inhibitors) or moderately severe to severe hemophilia B (HemB) (without inhibitors) as part of the SerpinPC registrational program.
• September 2023: Swedish Orphan Biovitrum announced a study of phase 4 clinical trials for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). The goal of this low-interventional study is to describe the overall joint health in patients with haemophilia A or haemophilia B prophylactically treated with rFVIIIFc or rFIXFc.
Request a sample and discover the recent advances in Hemophilia A Treatment Drugs @ Hemophilia A Pipeline Report- https://www.delveinsight.com/report-store/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Hemophilia A pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hemophilia A collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Hemophilia A Overview
Hemophilia A is an inherited bleeding disorder in which the blood does not clot normally. People with hemophilia A will bleed more than normal after an injury, surgery, or dental procedure. This disorder can be severe, moderate, or mild. In severe cases, heavy bleeding occurs after minor injury or even when there is no injury (spontaneous bleeding).
Find out more about Hemophilia A Treatment Landscape @ Drugs for Hemophilia A Treatment- https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Hemophilia A Emerging Drugs Profile
• AGN-193408: Allergan
• OCTA101: Octapharma
• Valoctocogene roxaparvovec: BioMarin Pharmaceuticals
Hemophilia A Pipeline Therapeutics Assessment
There are approx. 40+ key companies which are developing the Hemophilia A therapies. The Hemophilia A companies which have their Hemophilia A drug candidates in the most advanced stage, i.e. phase III include, Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd. and others.
Learn more about the emerging Hemophilia A Pipeline Therapies @ Hemophilia A Clinical Trials Assessment- https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Hemophilia A Pipeline Report
• Coverage- Global
• Hemophilia A Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hemophilia A Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Hemophilia A Companies- Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenix pharmaceutical, Spark Therapeutics, Octapharma, ApcinteX Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics LLC, CSL Behring, and others.
• Hemophilia A Pipeline Therapies- Emicizumab, rFVIIa, aPCC, BAX 888, OBIZUR, BIIB031 (rFVIIIFc), Recombinant Human Coagulation FVIII, and others.
Dive deep into rich insights for new drugs for Hemophilia A treatment, Visit @ Hemophilia A Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Hemophilia A: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hemophilia A - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Hemophilia A Collaboration Deals
9. Late Stage Products (Pre-registration)
10. Valoctocogene roxaparvovec: BioMarin Pharmaceutical
11. Late Stage Products (Phase III)
12. Giroctocogene fitelparvovec: Pfizer/ Sangamo Therapeutics
13. Mid Stage Products (Phase II)
14. NNC0365-3769 A (Mim8): Novo Nordisk A/S
15. Early Stage Products (Phase I/II)
16. BAX 888: Baxalta / Shire
17. BAY2599023: Bayer / Ultragenix pharmaceutical
18. Early Stage Products (Phase I)
19. Gene therapy: Expression Therapeutics, LLC
20. Drug profiles in the detailed report…..
21. Hemophilia A- Market Drivers and Barriers
22. Appendix
For further information on the Hemophilia A pipeline therapeutics, reach out to Hemophilia A Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Published Links
https://biomolecula.ru/authors/25303
https://discuss.machform.com/u/dennydones9191
https://dagshub.com/dennydones9191
https://careerkarma.com/profile/clr7d7z0c04v2lf3k5lrx9vyr/
https://gotech.mn.co/posts/48477911
https://landmarknew.mn.co/posts/48477947
https://infiniteabundance.mn.co/posts/48478016
https://wellbeingmatters.mn.co/posts/48478424
https://vrjam.mn.co/posts/48478544
https://decidim.santcugat.cat/profiles/dennydones9/activity
https://haveagood.holiday/users/336105
https://participa.rubi.cat/profiles/dennydones9191/activity
https://forum.callofwar.com/index.php?user/60304-dennydones9191/#about
https://dbook.mn.co/posts/48401881
https://lxgonline.mn.co/posts/navigating-the-landscape-of-hypertriglyceridemia-market-current-trends-and-future-prospects
https://www.penname.me/@dennydones99
https://community.fyers.in/member/7Yldtdsvui
https://spurstartup.mn.co/posts/48406045
https://pressurecooker.mn.co/posts/48406225
https://regenerative-future.mn.co/posts/navigating-the-hypertriglyceridemia-market-innovations-and-challenges
https://commiss.io/dennydones
https://www.pledgeme.co.nz/profiles/221820/
https://brave-comfort.mn.co/posts/48409148
https://gamebook.mn.co/posts/navigating-the-landscape-of-the-hypertriglyceridemia-market
https://kktix.com/user/5068280
https://network-373.mn.co/posts/48353213
https://body-imagine.mn.co/posts/48353364
https://pimpmyairgun.mn.co/posts/48353478
https://gtribe.mn.co/posts/advancements-and-opportunities-in-the-vulvar-cancer-market
https://communenour.mn.co/posts/emerging-trends-and-market-dynamics-in-vulvar-cancer-treatment
https://synkretic.mn.co/posts/understanding-the-vulvar-cancer-market-trends-challenges-and-innovations
https://jlfa2020.mn.co/members/16644457
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/graves-disease-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hemophilia A Pipeline, FDA Approvals, Clinical Trials Developments, and Companies | Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., and others. here
News-ID: 3347488 • Views: …
More Releases from DelveInsight Business Research LLP
Alpha-1 Protease Inhibitor Deficiency Market Size 2032: CSL Behring, Grifols The …
DelveInsight's "Alpha-1 Protease Inhibitor Deficiency Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Alpha-1 Protease Inhibitor Deficiency, historical and forecasted epidemiology as well as the Alpha-1 Protease Inhibitor Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Alpha-1 Protease Inhibitor Deficiency Market Research Report
• The increase in Alpha-1 Protease Inhibitor Deficiency Market Size…
Amyloidosis Market Size Report 2032: Attralus Inc., Novotech Pty Limited, Criter …
DelveInsight's "Amyloidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Amyloidosis, historical and forecasted epidemiology as well as the Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Amyloidosis Market Research Report
• The increase in Amyloidosis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies…
Basal Cell Nevus Syndrome Market Size Report 2032: Latest FDA Approvals, Emergin …
DelveInsight's "Basal Cell Nevus Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Nevus Syndrome, historical and forecasted epidemiology as well as the Basal Cell Nevus Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Basal Cell Nevus Syndrome Market Research Report
• The increase in Basal Cell Nevus Syndrome Market Size…
Biliary Atresia Market Size Report 2032: Latest FDA Approvlas and Pipeline Repor …
DelveInsight's "Biliary Atresia Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Key Takeaways from the Biliary Atresia Market Research Report
• The increase in Biliary Atresia Market Size is a direct consequence of the increasing…
More Releases for Hemophilia
Hemophilia Market
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand…
Hemophilia Therapeutics Pipeline Analysis Overview
The study analysed that the hemophilia pipeline comprises of 53 drug candidates in different stages of development.
The pipeline analysis based on route of administration of active drug candidates showed, that around most of the hemophilia drug candidates are being developed to be administered by intravenous route.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis
Most of the pharma and biotech companies are developing the therapeutics for hemophilia in collaboration with educational institutes. In…
Hemophilia B - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Hemophilia B - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H1 2017, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape.
Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include…
Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Koval …
ReportsWorldwide has announced the addition of a new report title Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement , Immune Tolerance Induction ) Outlook 2022 to its growing collection of premium market research reports.
Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged…
In-depth analysis of the Global Hemophilia Market: hemophilia A, hemophilia B, h …
Latest industry research report on: Global Hemophilia Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
Request For Sample Report @ http://www.marketresearchreports.biz/sample/sample/1064504
The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes…
Hemophilia Treatment Drugs Market Report 2024
Global Hemophilia Treatment Drugs Market: Overview
The global hemophilia treatment drugs market is presently catering to various sub-types of hemophilia such as hemophilia A, hemophilia B and others such as acquired hemophilia and hemophilia C. The increasing awareness of this disorder and the introduction of innovative ways of managing this disease has opened up several opportunities for the global market in recent years. According to the research report, the global hemophilia…